↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Träfflista för sökning "WFRF:(Novo JJ) "

Search: WFRF:(Novo JJ)

Result 1-10 of 10

Sort/group result

Sort by: Hits per page:

Enumeration	Reference	Cover	Find
1.	Bittner, VA, et al. (author) Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome 2020 In: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 75:2, s. 133-144 Journal article (peer-reviewed)
2.	Goodman, SG, et al. (author) Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery 2019 In: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 74:9, s. 1177-1186 Journal article (peer-reviewed)
3.	Jukema, JW, et al. (author) Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial 2019 In: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 74:9, s. 1167-1176 Journal article (peer-reviewed)
4.	Ray, KK, et al. (author) Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial 2019 In: The lancet. Diabetes & endocrinology. - 2213-8595 .- 2213-8587. ; 7:8, s. 618-628 Journal article (peer-reviewed)
5.	Roe, MT, et al. (author) Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes 2019 In: Circulation. - : Ovid Technologies (Wolters Kluwer Health). - 1524-4539 .- 0009-7322. ; 140:19, s. 1578-1589 Journal article (peer-reviewed)
6.	Schwartz, GG, et al. (author) Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome 2018 In: The New England journal of medicine. - : MASSACHUSETTS MEDICAL SOC. - 1533-4406 .- 0028-4793. ; 379:22, s. 2097-2107 Journal article (peer-reviewed)
7.	Szarek, M, et al. (author) Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial 2019 In: Circulation. Cardiovascular quality and outcomes. - : Ovid Technologies (Wolters Kluwer Health). - 1941-7705 .- 1941-7713. ; 12:11, s. e005858- Journal article (peer-reviewed)
8.	Szarek, M, et al. (author) Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial 2019 In: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 73:4, s. 387-396 Journal article (peer-reviewed)
9.	Lottspeich, F, et al. (author) EuPA achieves visibility – an activity report on the first three years 2008 In: Journal of Proteomics. - : Elsevier BV. - 1874-3919. ; 30:71, s. 11-18 Journal article (peer-reviewed)abstract Abstract in UndeterminedPlans for the European Proteomics Association (EuPA) were conceived and established during 2004 and 2005, and culminated in the formal inception of the Organisation during the 4th HUPO World Congress held in Munich in 2005. The mission from the outset has been three-tiered and is to: i) strengthen the national Proteomics organizations in their efforts; ii) to co-ordinate and provide educational programs, and iii) to advance the networking of scientists through meetings, workshops and student exchange. Linked to the mission were objectives to emphasise the benefits and contributions of Proteomics to biological and industrial researchers, the general public and science policy makers in Europe. in addition, the EuPA set out to promote scientific exchange for all applications and technology development related to Proteomics, and coordinate joint activities of national Proteomics societies at the European level. To achieve these tasks an organisational. structure was conceived whereby four Activity Committees (Conferences/Communications, Education, EuPA-HUPO-Interactions and Funding) were implemented and a General Council consisting of all member countries. The remarkable rise and progress the EuPA has achieved in this small time frame is reported here.
10.	Orr, N, et al. (author) Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2 2015 In: Human molecular genetics. - : Oxford University Press (OUP). - 1460-2083 .- 0964-6906. ; 24:10, s. 2966-2984 Journal article (peer-reviewed)

Skapa referenser, mejla, bekava och länka

Permalink

Result 1-10 of 10

Refine your search

Type of publication: journal article (10)

Type of content: peer-reviewed (10)

Author/Editor: King, M. (8); Li, Y. (8); Schmidt, E. (8); Zaman, A. (8); Zhang, Z. (8); Zhu, H. (8); show more...; Guo, Y (8); Ahmed, H. (8); Kaiser, S. (8); Nikolaev, K. (8); Schwartz, M. (8); Kumar, A. (8); Robinson, S. (8); Zheng, Y. (8); Costa, F. (8); Das, S. (8); Diaz, R. (8); Mahajan, A. (8); Davies, R (8); Aggarwal, R. (8); Andersen, K (8); Diaz, A. (8); Cohen, S. (8); Rosenberg, M. (8); Gullestad, L (8); Hong, T. (8); Kumar, P. (8); Khan, A. (8); Davis, W. (8); Aboyans, V (8); Khan, M (8); Liu, SW (8); Pandey, A (8); Sarkar, D. (8); Hoffman, D (8); Takahashi, T. (8); Marx, R. (8); Bottcher, M. (8); White, M. (8); Seferovic, P (8); Wells, T (8); Katz, A. (8); Ito, K. (8); Kobayashi-, J (8); Anderson, J. (8); Harding, S (8); Huang, L. (8); Vulic, D (8); Pearce, S (8); Gerber, J. (8); show less...

University: Karolinska Institutet (9); Uppsala University (8); Lund University (1)

Language: English (10)

Research subject (UKÄ/SCB): Medical and Health Sciences (9)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - National Library Systems
LIBRIS.kb.se

pil uppåt

Close

Copy and save the link in order to return to this view